



Atypical Antipsychotics Prior Authorization Request Form (Page 1 of 4)

Note: If the following information is NOT filled in completely, correctly, or legibly the PA process **may** be delayed.
Please complete one form per member.

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Is this a tapering off dose for discontinuation? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select the diagnosis below: <input type="checkbox"/> Chronic Aggression <input type="checkbox"/> Depressive Episodes of Bipolar Disorder (Bipolar Depression) <input type="checkbox"/> Major Depressive Disorder (MDD) <input type="checkbox"/> Major Depressive Disorder with Psychosis <input type="checkbox"/> Manic or Mixed Episodes of Bipolar Disorder <input type="checkbox"/> Oppositional Defiant Disorder <input type="checkbox"/> Pervasive Developmental Disorder (PDD)/Autism/Irritability associated with Autism/PDD <input type="checkbox"/> Schizophrenia/Schizoaffective Disorder <input type="checkbox"/> Suicidal Behavior associated with Schizophrenia/Schizoaffective Disorder <input type="checkbox"/> Tics <input type="checkbox"/> Tourette's Disorder <input type="checkbox"/> Treatment-Resistant Major Depressive Disorder (MDD) <input type="checkbox"/> Treatment-Resistant Schizophrenia/Schizoaffective Disorder <input type="checkbox"/> Other (specify): _____					
Answer the following: Is the member being referred to a psychiatrist and awaiting an appointment? <input type="checkbox"/> Yes <input type="checkbox"/> No Date of appointment: _____ Psychiatrist: _____ What is the member's age in years? <input type="checkbox"/> ≥18 <input type="checkbox"/> 10-17 <input type="checkbox"/> 6-9 <input type="checkbox"/> 5 <input type="checkbox"/> <5 Is there a monitoring plan/will the member be monitored for evaluating safety and effectiveness of the medication? <input type="checkbox"/> Yes <input type="checkbox"/> No					



Atypical Antipsychotics Prior Authorization Request Form (Page 2 of 4)

If the member is younger than FDA-approved age for medication(s) requested, please complete section E (page 4)

Medication Generic Name (Brand Name)	Under FDA-Approved Age
Aripiprazole oral disintegrating tablets (Abilify Discmelt)	<6 years of age for autism/PDD or Tourette's; <10 years of age for bipolar; <13 years of age for schizophrenia; <18 years of age for MDD
Aripiprazole tablets and oral solution (Abilify)	<6 years of age for autism/PDD or Tourette's; <10 years of age for other diagnoses
Aripiprazole tablets with sensor and long-acting injection (Abilify Asimtufii, Abilify Maintena, Abilify MyCite, Aristada, Aristada Initio)	<18 years of age
Asenapine sublingual tablets (Saphris)	<10 years of age for bipolar; <18 years of age for schizophrenia
Asenapine transdermal patch (Secuado)	<18 years of age
Brexpiprazole (Rexulti)	<18 years of age for MDD; <13 years of age for schizophrenia
Cariprazine (Vraylar)	<18 years of age
Clozapine (Clozaril, FazaClo, Versacloz)	<18 years of age
Iloperidone (Fanapt)	<18 years of age
Lumateperone (Caplyta)	<18 years of age
Lurasidone (Latuda)	<10 years of age for bipolar depression; <13 years of age for other diagnoses
Olanzapine (Zyprexa, Zyprexa Zydis)	<10 years of age for bipolar depression; <13 years of age for other diagnoses
Olanzapine long-acting injection (Zyprexa Relprevv)	<18 years of age
Olanzapine/fluoxetine (Symbyax)	<18 years of age for treatment-resistant MDD; <10 years of age for bipolar depression
Olanzapine/samidorphan (Lybalvi)	<18 years of age
Paliperidone (Invega)	<12 years of age
Paliperidone long-acting injection (Invega Hafyera, Invega Sustenna, Invega Trinza)	<18 years of age
Quetiapine immediate-release (Seroquel)	<10 years of age
Quetiapine extended-release (Seroquel XR)	<10 years of age
Risperidone (Risperdal, Risperdal M-Tab)	<5 years of age for autism/PDD; <10 years of age for other diagnoses
Risperidone extended-release injection (Perseris, Uzedy)	<18 years of age
Risperidone long-acting injection (Risperdal Consta)	<18 years of age
Ziprasidone (Geodon)	<18 years of age

NOTE: Section A or B MUST be completed below.

SECTION A: The member has been established on the requested medication

How long has the member been taking the requested medication? < 2 weeks ≥ 2 weeks

Has the member shown improvement in symptoms while on the requested medication? Yes No

If **yes**, please check one or more boxes below for areas of improvement:

- | | |
|--|---|
| <input type="checkbox"/> Blunted affect | <input type="checkbox"/> Hallucinatory behavior |
| <input type="checkbox"/> Conceptual disorganization | <input type="checkbox"/> Hostility |
| <input type="checkbox"/> Delusions | <input type="checkbox"/> Lack of spontaneity and flow of conversation |
| <input type="checkbox"/> Depressive symptoms | <input type="checkbox"/> Passive/apathetic social withdrawal |
| <input type="checkbox"/> Difficulty in abstract thinking | <input type="checkbox"/> Poor rapport |
| <input type="checkbox"/> Emotional withdrawal | <input type="checkbox"/> Stereotyped thinking |
| <input type="checkbox"/> Excitement | <input type="checkbox"/> Suicidal thoughts |
| <input type="checkbox"/> Grandiosity | <input type="checkbox"/> Suspiciousness/persecution |
| <input type="checkbox"/> Other: _____ | |



Atypical Antipsychotics Prior Authorization Request Form (Page 3 of 4)

SECTION B: The member has never taken the requested medication

Which of the following preferred medications has the member tried? (check all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Aripiprazole Dates: _____ | <input type="checkbox"/> Ziprasidone Dates: _____ | <input type="checkbox"/> Olanzapine Dates: _____ |
| <input type="checkbox"/> Risperidone Dates: _____ | <input type="checkbox"/> Quetiapine IR/ER Dates: _____ | <input type="checkbox"/> Lurasidone Dates: _____ |
| <input type="checkbox"/> Paliperidone Dates: _____ | <input type="checkbox"/> Fanapt Dates: _____ | <input type="checkbox"/> Vraylar Dates: _____ |
| <input type="checkbox"/> Rexulti Dates: _____ | <input type="checkbox"/> Caplyta Dates: _____ | <input type="checkbox"/> None |

Reason the following preferred medications are not appropriate for the member (complete for each applicable drug in the following table).

Drug	Reason inappropriate choice for member
Aripiprazole	
Caplyta	
Fanapt	
Lurasidone	
Olanzapine	
Paliperidone	
Rexulti	
Risperidone	
Quetiapine IR/ER	
Vraylar	
Ziprasidone	

For aripiprazole, Rexulti, quetiapine extended-release, Vraylar and olanzapine-fluoxetine for major depressive disorder only: Reason antidepressant monotherapy is not adequate for the member. (complete for each drug/class)

Drug	List medication name, response, and dates of therapy
SNRIs (desvenlafaxine, duloxetine, venlafaxine)	
SSRIs (citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline)	
Other Antidepressants (bupropion, mirtazapine, trazodone, vortioxetine; list may not be all inclusive)	

SECTION C. If an orally disintegrating tablet, oral solution or transdermal patch is being requested, also answer the following:

What prevents the member from taking a solid oral dosage formulation? (check all that apply)

- Dysphagia
 Compliance monitoring required
 Dose cannot be obtained from solid oral dosage form
 Other (specify): _____

SECTION D. If Abilify Asimtufii, Abilify Maintena, Aristada, Aristada Initio, Invega Hafyera, Invega Sustenna, Invega Trinza, Perseris, Risperdal Consta, Uzedy, or Zyprexa Relprevv is being requested, also answer the following:

Has the member tried oral aripiprazole (if Abilify Asimtufii, Abilify Maintena, Aristada or Aristada Initio is being requested), oral risperidone or oral paliperidone (if Risperdal Consta or Invega Sustenna is being requested), oral risperidone or oral paliperidone (if Perseris or Uzedy are being requested), Invega Sustenna (if Invega Trinza is being requested), Invega Sustenna or Invega Trinza (if Invega Hafyera is being requested) or oral olanzapine (if Zyprexa Relprevv is being requested) or does the member have a history of noncompliance with oral medications and is unable to receive a trial of the appropriate oral atypical antipsychotic before starting long-acting therapy with injection or is the member unable to swallow or use orally disintegrating tablets?

Yes Date of last therapy: _____ **No**

Is the prescribing physician a psychiatrist or has a psychiatrist been consulted? **Yes** **No**

Where will the medication be administered?

- Home or other outpatient pharmacy setting by a trained health care professional
 Long-term care facility
 CSB (Community Service Board)
 Physician office or clinic**
 Other (specify): _____

** If you are requesting for authorization for administration in a physician's office or clinic other than a CSB, please go to the Registered User portion of the Georgia Health Partnership website at <https://www.mmis.georgia.gov/portal> to request a PA from Physician Services.



Atypical Antipsychotics Prior Authorization Request Form (Page 4 of 4)

SECTION E: In the space below, please provide letter of medical necessity and any additional information you deem clinically relevant in evaluating the prior authorization request:

Physician signature: _____

Contact person: _____ **Phone:** _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-866-525-5827.
This form may be used for non-urgent requests and faxed to 1-888-491-9742.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: AtypicalAntipsychotics_GAM_2023December